Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Vitamin D3 ameliorates R-loop-induced replication stress and chromosomal instability in MED12-mutant uterine fibroids.

Scientific reports·2026
Same author

Long-term outcomes of evolving treatment regimens in Ewing sarcoma survivors diagnosed 1970-1999: A report from the Childhood Cancer Survivor Study.

Cancer·2026
Same author

Biochemical, structural and mutational landscapes of base excision repair enzymes and cancer: from atomic resolution to tumor signatures.

International journal of radiation biology·2026
Same author

Bidirectional associations between cannabis use, oddball performance and P3 event-related potential.

medRxiv : the preprint server for health sciences·2026
Same author

Feasibility and pharmacokinetic evaluation of a needle-free injector for delivering high concentration antibody formulations.

Bioengineering & translational medicine·2026
Same author

A case of eosinophilic dermatosis of hematologic malignancy treated with omalizumab.

JAAD case reports·2026

Related Experiment Video

Updated: May 17, 2026

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody
07:36

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody

Published on: May 16, 2020

Targeting cancer with a lupus autoantibody.

James E Hansen1, Grace Chan, Yanfeng Liu

  • 1Department of Therapeutic Radiology, Yale School of Medicine, New Haven, CT 06520, USA. james.e.hansen@yale.edu

Science Translational Medicine
|October 27, 2012
PubMed
Summary

A lupus autoantibody, 3E10, targets DNA repair deficiencies in cancers. This antibody shows potential for treating BRCA2-deficient tumors, like breast and ovarian cancers, offering a novel therapeutic strategy.

More Related Videos

Using X-ray Crystallography, Biophysics, and Functional Assays to Determine the Mechanisms Governing T-cell Receptor Recognition of Cancer Antigens
09:53

Using X-ray Crystallography, Biophysics, and Functional Assays to Determine the Mechanisms Governing T-cell Receptor Recognition of Cancer Antigens

Published on: February 6, 2017

A Syngeneic Mouse B-Cell Lymphoma Model for Pre-Clinical Evaluation of CD19 CAR T Cells
12:16

A Syngeneic Mouse B-Cell Lymphoma Model for Pre-Clinical Evaluation of CD19 CAR T Cells

Published on: October 16, 2018

Related Experiment Videos

Last Updated: May 17, 2026

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody
07:36

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody

Published on: May 16, 2020

Using X-ray Crystallography, Biophysics, and Functional Assays to Determine the Mechanisms Governing T-cell Receptor Recognition of Cancer Antigens
09:53

Using X-ray Crystallography, Biophysics, and Functional Assays to Determine the Mechanisms Governing T-cell Receptor Recognition of Cancer Antigens

Published on: February 6, 2017

A Syngeneic Mouse B-Cell Lymphoma Model for Pre-Clinical Evaluation of CD19 CAR T Cells
12:16

A Syngeneic Mouse B-Cell Lymphoma Model for Pre-Clinical Evaluation of CD19 CAR T Cells

Published on: October 16, 2018

Area of Science:

  • Immunology
  • Oncology
  • Molecular Biology

Background:

  • Systemic lupus erythematosus (SLE) is characterized by autoantibodies against host DNA.
  • The role of anti-DNA antibodies in SLE pathogenesis is unclear.
  • Lupus autoantibodies have not been explored for cancer therapy.

Purpose of the Study:

  • To investigate the potential of a lupus autoantibody, 3E10, as a targeted cancer therapy.
  • To explore 3E10's mechanism of action in DNA repair and its effect on cancer cells.

Main Methods:

  • Assessed 3E10 binding to DNA single-strand tails.
  • Evaluated 3E10's inhibition of DNA single-strand and double-strand break repair.
  • Tested 3E10's efficacy in sensitizing cultured tumor cells and xenografts to DNA-damaging agents (doxorubicin, radiation).
  • Determined 3E10's synthetic lethality in BRCA2-deficient cancer cells.

Main Results:

  • 3E10 preferentially binds DNA single-strand tails.
  • 3E10 inhibits key DNA repair pathways.
  • 3E10 sensitizes tumor cells and xenografts to chemotherapy and radiation.
  • 3E10 is synthetically lethal to BRCA2-deficient cancer cells, enhancing sensitivity to doxorubicin.

Conclusions:

  • The lupus autoantibody 3E10 shows promise as a targeted therapy for DNA repair-deficient malignancies, particularly BRCA2-related cancers.
  • Lupus autoantibodies may represent a source of novel therapeutic agents for cancer treatment.
  • Findings suggest lupus autoantibodies might contribute to DNA repair deficiencies and cancer incidence in SLE patients.